TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: Level of vigilance and sustained attention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Prostate Symptoms Score improvement percentage
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Re-tear rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Diaphragm stiffness
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Increase of Hemoglobin Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Proportion complete
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Reduction of IOP greater than or equal to 20%
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Forced expiratory volume on first second (FEV1)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Prevalence of microbial colonization
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Musculoskeletal Health
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Serum eotaxin levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Opsonophagocytic antibody titers for pneumococcal vaccine serotypes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: RSV-A neutralizing antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: RSV-B neutralizing antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Complete response after 6 cycles of treatment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Accelerometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of Participants With Abnormal Clinical Safety Laboratory Adverse Events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of Participants With Protocol-specified Adverse Events of Special Interest (AESIs)
Endpoint domain: Adverse events/effects
Primary endpoint: Inflammatory blood markers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: percentage of cocaine-positive/missing urines
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intraoperative Effective Hemostasis
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Area under the ROC curve of ABMR rejection prediction models
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Quality of life evaluated by EQ-5D-5L questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life during therapy by FACT-G scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life during therapy by FACT-EGFRI-18 scale
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in Non-invasive Tear Break Up Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: accuracy of stroke volume estimation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Number of Participants who Find the Intervention Acceptable
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Find Intervention Feasible
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Number of Participants Who Indicate Barriers to Therapy Were Decreased
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: corrected age at detection of early signs of CP
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Developmental functioning at 18-24 month CA
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Helpful/empathetic responses toward medical mistrust
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Provider use of strategies learned in the provider intervention
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Assessment of treatment emergent adverse events (AEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Establish Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD)
Endpoint domain: Adverse events/effects
Primary endpoint: Intimate partner violence incidence
Endpoint domain: Adverse events/effects
Primary endpoint: Change in log 10 viral load
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Preliminary clinical benefit of CAP-100 monotherapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with >= 2-fold increase in TIICs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Satisfaction with Social Activities
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Time in conversations
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Time outside the home
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Visualization of membranes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Variation in poorly aerated lung volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Variation in non-aereted lung volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Incidence of PVD
Endpoint domain: Physiological/clinical
Endpoint subdomain: Ocular outcomes
Primary endpoint: Induction and recovery time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak Right Ventricular - Pulmonary Coupling
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Mother-Baby Attachment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proteinuria (log)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Percentage of time in range (TIR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Incidence of treatments on quality of life assessed by EORTIC QLQ-C30
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Efficacy of the intervention
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-dependent composite clinical endpoint
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Low anterior resection syndrome (LARS) score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Axis orientation of lenses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Sensitivity and specificity of XTR006 PET imaging
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Decrease in bacterial concentrations greater than 105 CFU/mL
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Area Under the Concentration-Time Curve to Infinity (AUCinf)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Plasma Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in serum fructose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Number/Rate of words learned
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Diagnostic accuracy of neck masses
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pin-prick test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Pain Score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy analysis using Tip Apex Distance (TAD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of subjects with no all-cause death
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of subjects with no heart failure readmitted
Endpoint domain: Mortality/survival
Primary endpoint: Percentage of subjects with NYHA increased by one grade or more
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Percentage of subjects with TR decreased ≥1+
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Endothelial changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in pain score assessed by the PROMIS 3a
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in narcotic usage
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Change in pain score assessed by the NRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Geometric Mean Titers (GMTs) of SARS-CoV-2 neutralizing titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Percentage with seroresponse to SARS-CoV-2 Omicron (XBB.1.5)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Fugl- Meyer Upper extremity scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Action arm research test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction of eye pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility as measured by study accrual
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Lab safety tests
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Recommended Phase II Dose (RPIID)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: M-FIM
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Frequency characteristics of the photoplethysmography (PPG) signal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: ACM cells in maternal blood
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analog Scale for Craving (VASC)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Visual Analog Scale Anxiety (VASA)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Proportion of participants with positive urine toxicology
Endpoint domain: Adverse events/effects
Primary endpoint: Death occurrence within one year of follow up
Endpoint domain: Mortality/survival
Primary endpoint: 24 hours blood pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change of dipping of blood pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Participant Enrollment Rate
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Number of participants with Clinical Remission
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: recurrence rate of AF within a year in all participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: recurrence rate of AF within a year in ablated participants
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Unplanned return to the ICU
Endpoint domain: Adverse events/effects
Primary endpoint: Iron levels in cerebrospinal fluid (CSF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change Visuospatial memory
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Change Flexibility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change Inhibition with witty
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cognitive functioning
Primary endpoint: Time >800 ppm CO2
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Feasibility of a fatigability test
Endpoint domain: Physiological/clinical
Endpoint subdomain: Fatigue
Primary endpoint: Change in Overall Abstinence
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Duration of gastric contractility
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: MRE images
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Early AVF failure (eAVFF)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Morbidity rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Daily time spent normoxic
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: American Shoulder and Elbow Surgeons (ASES) Assessment Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Prenatal Breastfeeding Self-Efficacy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in cannabis cue-elicited brain activation (fMRI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Alcohol self-administration
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Acceptability of the CCAPB intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Respiratory Health-related quality of life
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Follow-up Completion
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Lens densitometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in arm/hand skill training
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence of all-grade cytokine release syndrome
Endpoint domain: Adverse events/effects
Primary endpoint: Mean change in scores on the Test of Variables of Attention (TOVA) over time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mean changes in Adaptive Cognitive Evaluation (ACE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of participants who experienced treatment-related adverse events
Endpoint domain: Adverse events/effects
Primary endpoint: Feasibility of study drug administration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: IFT response
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in GAF
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Changes in MADRS
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Alpha-1-Antitrypsin
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Modified Tardiue Scale (MTS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NMC Tests with Seansamove Sensbalance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hip excursion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Prevalence of Chlamydia trachomatis infection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Safety of the EGCG Intervention
Endpoint domain: Adverse events/effects
Primary endpoint: change in assessment of postoperative pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Detection of lncRNA SNHG15
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change in online self-awareness
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Maximum Expiratory Pressure (MEP) Between Pre and Post Respiratory Strength Training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Maximum Inspiratory Pressure (MIP) Pre and Post Respiratory Strength Training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Change in Cough Peak Expiratory Flow Between Pre and Post Respiratory Strength Training
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Initiation or intensification of lipid-lowering therapy
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Safety and tolerability of (PEG)-BHD1028
Endpoint domain: Adverse events/effects
Primary endpoint: objective pain perception
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of Domestic Violence Experiences
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: Prevalence of Psychological Distress
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of Post-Traumatic Stress Disorder
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Prevalence of Suicidality Risk
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Lesion Reduction and Re-epithelization - Definitive Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Lesion Reduction and Re-epithelization - Partial Cure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Breastfeeding success measurement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in Volatile Organic Compounds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Dynamic balance and functional mobility
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Efficacy of uterocervical angle
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Score on Feasibility of Intervention Measure (FIM) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Score on Acceptability of Intervention Measure (AIM) Questionnaire
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Proportion of patient participants with subsequent follow-up visit within 3 months
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Percentage of Participants With EASI-75 Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Expression of Klotho and LRP-6 proteins
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Mini sleep questionnaire (MSQ)
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Numerical rating scale-11 score for pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area Under the Concentration-time Curve, From Time 0 to 24 Hours Post-dose (AUC0-24) of Pirtobrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum observed concentration (Cmax) of Pirtobrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Apparent Systemic Clearance (CL/F) of Pirtobrutinib
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Coefficient of Variance of the difference between lab results and Liberty results
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive success rate of LBBAP utilization
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change of fluoroscopy/procedure duration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Fugl-Meyer Assessment of Upper Extremity (FMA-UE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort as Assessed by Visual Analog Scale (VAS)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Response rate of Complete Spontaneous Bowel Movements (CSBM)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Overall perimenopause clinical symptoms severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change rate of lumbar bone mineral density (BMD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Brain function & structure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Reward processing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Normal length of the nail plate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal width of the nail plate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Normal curvature of the nail plate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Acceptability of the pacifier
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Change in the Yale-Brown Obsessive-Compulsive Scale (YBOCS) total score from baseline
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of genomic results returned
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in gout pain intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in fluctuation-related pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes